株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

COPD (慢性閉塞性肺疾患) 治療薬の世界市場の分析:予測

Global COPD Drugs Market - Analysis By Drug Type (Combination Therapy, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country: 2019 Edition, Forecast to 2023

発行 Azoth Analytics 商品コード 798091
出版日 ページ情報 英文 255 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.08円で換算しております。
Back to Top
COPD (慢性閉塞性肺疾患) 治療薬の世界市場の分析:予測 Global COPD Drugs Market - Analysis By Drug Type (Combination Therapy, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country: 2019 Edition, Forecast to 2023
出版日: 2019年02月28日 ページ情報: 英文 255 Pages
概要

当レポートでは、世界のCOPD (慢性閉塞性肺疾患) 治療薬市場について調査分析し、統計と情報 (市場規模・シェア・成長要因) のほか、新興動向、主要促進要因、課題と機会、主要企業について、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 戦略的提言

第4章 COPD治療用製剤の見通し

第5章 世界のCOPD治療薬市場:成長率と予測

  • 金額別 (実績)
  • 金額別 (予測)

第6章 世界のCOPD治療薬市場:セグメント別分析

  • 薬剤タイプ別:内訳
    • 併用療法
    • 抗コリン薬
    • β作動薬
    • ICS
    • その他
  • 市場の魅力:薬剤タイプ別

第7章 世界のCOPD治療薬市場:地域別分析

  • 地域別:内訳

第8章 北米のCOPD治療薬市場:成長率と予測

  • セグメント別分析
  • 薬剤タイプ別:内訳
  • 国別分析

第9章 欧州のCOPD治療薬市場:成長率と予測

  • セグメント別分析
  • 薬剤タイプ別:内訳
  • 国別分析

第10章 アジア太平洋地域のCOPD治療薬市場:成長率と予測

  • セグメント別分析
  • 薬剤タイプ別:内訳
  • 国別分析

第11章 その他の地域のCOPD治療薬市場:成長率と予測

  • セグメント別分析
  • 薬剤タイプ別:内訳
  • 国別分析

第12章 世界のCOPD治療薬市場:パイプライン分析

第13章 世界のCOPD治療薬市場:市場力学

  • 促進要因
  • 抑制要因
  • 動向
  • 製品ベンチマーキング
  • 売上分析:企業別

第14章 ファイブフォース分析

第15章 SWOT分析

第16章 企業プロファイル

  • GSK
  • AstraZeneca
  • Boehringer-Ingelheim
  • Teva Pharmaceuticals
  • Chiesi Farmaceutici S.p.A.
  • Novartis
  • Cipla
  • Mylan
  • Vectura Group Plc,
  • Sunovion
図表

List of Figures

  • Figure 1: Management of COPD
  • Figure 2: Global COPD Drugs Market Size, By Value, 2013-2017 (USD Million)
  • Figure 3: Smoking Prevalence Among Adults, By Gender, 2015
  • Figure 4: Cigarette Sales Share, By Region, 2017 (% of total)
  • Figure 5: Deaths Due To Air Pollution, By Disease Type, 2016
  • Figure 6: Percentage of NCD Cases Due to Air Pollution, 2016
  • Figure 7: Global PM2.5 air pollution, mean annual exposure, 2012-2016
  • Figure 8: Global Aged Population(Above 65), By Country, 2017 (% of total)
  • Figure 9: Global Aged Population (Above 65), 2013-2017 (% of total)
  • Figure 10: Global Overweight Population (Age above 18), 2013-2016 (% of total)
  • Figure 11: Global Overweight Population (Age above 18), By Sex, 2016 (% of total)
  • Figure 12: COPD Facts and Figures
  • Figure 13: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region
  • Figure 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
  • Figure 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
  • Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
  • Figure 17: COPD DAYLs Per 100000, By Country, All Sex, All Age,2017
  • Figure 18: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
  • Figure 19: Global Expected Healthcare Industry Outlook
  • Figure 20: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 21: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 22: Global COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 23: Global COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 24: Global Combination Therapy COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 25: Global Combination Therapy COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 26: Global Anticholinergics COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 27: Global Anticholinergics COPD Drugs Market, 2018-2023(USD Million)
  • Figure 28: Global Beta-Agonist COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 29: Global Beta-Agonist COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 30: Global ICS COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 31: Global ICS COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 32: Global Other COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 33: Global Other COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 34: Global Market Attractiveness, By Product Type, 2023F
  • Figure 35: Global COPD Drugs Market Size, By Region, 2017 (%)
  • Figure 36: Global COPD Drugs Market Size, By Region, 2023F (%)
  • Figure 37: North America COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 38: United States Spending on Medicines, 2013-2017 (In USD Billion)
  • Figure 39: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)
  • Figure 40: North America, Smoking Prevalence, Age 15+, 2013-2016
  • Figure 41: North America, Smoking Prevalence, Age 15+, 2013-2016
  • Figure 42: United States health care expenditure per capita,2013-2016(USD)
  • Figure 43: Canada health care expenditure per capita,2013-2016(USD)
  • Figure 44: North America population aged 65 and above, 2013-2017 (% of total)
  • Figure 45: North America Healthcare Cost Per Capita, 2017 (USD)
  • Figure 46: North America GDP per Capita, 2013-2017 (USD)
  • Figure 47: North America COPD Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 48: North America COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 49: North America COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 50: North America COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 51: North America COPD Drugs Market, By Drug Type , By Value, 2018-2023(USD Million)
  • Figure 52: North America COPD Drugs Market Size, By Countries, 2017 (%)
  • Figure 53: North America COPD Drugs Market Size, By Countries, 2023F (%)
  • Figure 54: USA COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 55: USA COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 56: Smoking Prevalence, Age 15+, 2012-2016
  • Figure 57: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 58: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
  • Figure 59: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)
  • Figure 60: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
  • Figure 61: U.S., Population ages 65 and above, 2013-2017 (% of total)
  • Figure 62: U.S., Population ages 65 and above, Forecast (In Millions)
  • Figure 63: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD)
  • Figure 64: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
  • Figure 65: USA COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 66: USA COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 67: USA COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 68: USA COPD Drugs Market, By Drug Type, By Value, 2018-2023(USD Million)
  • Figure 69: Canada COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 70: Canada COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 71: Percentage Change in Deaths Between, 2007-2017 Due to Respiratory Diseases
  • Figure 72: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 73: Canada, Smoking Prevalence, Age 15+, 2012-2016
  • Figure 74: Number of Retail Pharmacies in Canada, 2013-2017
  • Figure 75: Number of Hospitals Establishments in Canada, By Province, 2015
  • Figure 76: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
  • Figure 77: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 78: Canada, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 79: Canada COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 80: Canada COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 81: Canada COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 82: Europe COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 83: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
  • Figure 84: Europe Population ages 65 years and above (% of total population), 2013-17
  • Figure 85: European Union, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 86: European Union, Smoking Prevalence, Age 15+, 2012-2016
  • Figure 87: Cause of Death, EU-28, 2015, Per 1000000 inhabitants, Both Sex
  • Figure 88: Europe, COPD Prevalence, By Selected Countries, 2017, (In Million)
  • Figure 89: Mean Average Age At Which Majority of Population Affected By COPD, By Region
  • Figure 90: Europe COPD Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 91: Europe COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 92: Europe COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 93: Europe COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 94: Europe COPD Drugs Market Size, By Countries, 2017 (%)
  • Figure 95: Europe COPD Drugs Market Size, By Countries, 2023F (%)
  • Figure 96: Germany COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 97: Germany COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 98: Germany COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions)
  • Figure 99: PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 100: Germany, Population ages 65 and above, 2012-2017 (% total)
  • Figure 101: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 102: Germany, Healthcare Related Statistics, 2017
  • Figure 103: Germany, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)
  • Figure 104: Germany, Percentage Change In Cause of Death Between 2007-2017
  • Figure 105: Germany COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 106: Germany COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 107: Germany COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 108: France COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 109: France COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 110: France, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions)
  • Figure 111: France, Smoking Prevalence, Age 15+, 2012-2017, (% of Total)
  • Figure 112: France, Healthcare Infrastructure Related Statistics
  • Figure 113: France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2017
  • Figure 114: France, Health Expenditure, (% of GDP), 2012-2015 (USD)
  • Figure 115: France, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 116: France, Cause of Death, 2017, (% of Total)
  • Figure 117: France, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 118: France COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 119: France COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 120: France COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 121: U.K COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 122: U.K COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 123: Germany, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions)
  • Figure 124: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
  • Figure 125: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 126: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 127: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 128: UK, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017
  • Figure 129: UK, Smoking Prevalence (% of Total), 2012-2017
  • Figure 130: U.K COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 131: U.K COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 132: U.K COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 133: Italy COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 134: Italy COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 135: Italy COPD Prevalence, 2013-2017, 2018E-2023E, (in Millions)
  • Figure 136: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD)
  • Figure 137: Italy, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 138: Italy, Healthcare Infrastructure Related Statistics
  • Figure 139: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 140: Italy, Smoking Prevalence, Age 15+, 2012-2016
  • Figure 141: Italy, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter) 2012-2016
  • Figure 142: Italy COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 143: Italy COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 144: Italy COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 145: APAC COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 146: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
  • Figure 147: Population ages 65 and above, By Select Country, 2017 (% of total)
  • Figure 148: Men Smoking Prevalence in Asia, 2016, (% of Total Population)
  • Figure 149: East Asia & Pacific, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 150: South Asia, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 151: China, Pharmaceuticals Industry Revenue (USD Billion)
  • Figure 152: Japan, Total Drugs Market, 2013-2017, USD Billion
  • Figure 153: India Pharma Market, 2015-2017, (USD Billion)
  • Figure 154: APAC COPD Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 155: APAC COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 156: APAC COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 157: APAC COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 158: APAC COPD Drugs Market Size, By Countries, 2017 (%)
  • Figure 159: APAC COPD Drugs Market Size, By Countries, 2023F (%)
  • Figure 160: China COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 161: China COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 162: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016
  • Figure 163: China, Tobacco Attributable Deaths, 2030
  • Figure 164: China, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 165: Beijing annual PM2.5 air pollution levels, 2013-2017, ( in micrograms per cubic meter of air)
  • Figure 166: China Co2 Emissions, 2013-2016 (Billion Metric Tons)
  • Figure 167: China, Population Above 65 (% of Total), 2013-2017
  • Figure 168: China, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 169: China, Share of Urban Population, 2012-2017 (In %)
  • Figure 170: China, Total Population, 2013-2021F (In Billion)
  • Figure 171: China COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 172: China COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 173: China COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 174: Japan COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 175: Japan COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 176: Japan, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 177: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence)
  • Figure 178: Japan, Medical Facilities Outlook
  • Figure 179: Japan Healthcare Expenditure Outlook (%)
  • Figure 180: Japan, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016
  • Figure 181: Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 182: Japan COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 183: Japan COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 184: Japan COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 185: India COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 186: India COPD Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 187: India, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017
  • Figure 188: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)
  • Figure 189: India, Diseases & Medical Industry Outlook
  • Figure 190: India, Population ages 65 and above, 2013-2017
  • Figure 191: India, Total Population, 2013-2023F (In Billion)
  • Figure 192: Pharma Export From India Market, 2013-2017, (USD Billion)
  • Figure 193: India COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 194: India COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 195: India COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 196: ROW COPD Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 197: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016
  • Figure 198: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016
  • Figure 199: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
  • Figure 200: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
  • Figure 201: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
  • Figure 202: Middle East and North Africa, Population ages 65 and above (% of total)
  • Figure 203: ROW COPD Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 204: ROW COPD Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 205: ROW COPD Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 206: ROW COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 207: Exacerbation During the Study Over a Period of 12 Months (Part B)
  • Figure 208: Percentage aged 60 years and over, (2000, 2015, 2030,2050)
  • Figure 209: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million)
  • Figure 210: GSK COPD Drugs Sales, 2018-2023 Estimated, USD Million
  • Figure 211: AstraZeneca COPD Drugs Sales, 2018-2023 Estimated, USD Million
  • Figure 212: Novartis COPD Drugs Sales, 2018-2023 Estimated, USD Million
  • Figure 213: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million)
  • Figure 214: GSK, Revenues, 2013-2017 (USD Million)
  • Figure 215: GSK, Revenues, 2013-2017 (USD Million)
  • Figure 216: GSK, Revenue, By Segments, 2017(%)
  • Figure 217: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million)
  • Figure 218: GSK COPD Drugs Patent Expiry Details
  • Figure 219: GSK, Respiratory Segment Expected Revenue By 2023 (USD Million)
  • Figure 220: AstraZeneca, Net Sales, 2013-2017 (USD Million)
  • Figure 221: AstraZeneca Revenue, By Segments, 2017(%)
  • Figure 222: AstraZeneca Revenue, By Region, 2017(%)
  • Figure 223: Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million)
  • Figure 224: Boehringer-Ingelheim, By Segments, 2017(%)
  • Figure 225: Boehringer-Ingelheim, By Region, 2017(%)
  • Figure 226: Teva Pharmaceuticals, Net Sales, 2013-2017 (USD Million)
  • Figure 227: Teva Pharmaceuticals, By Segments, 2017(%)
  • Figure 228: Teva Pharmaceuticals, By Region, 2017(%)
  • Figure 229: Chiesi Farmaceutici S.p.A. , Net Sales, 2013-2017 (USD Million)
  • Figure 230: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%)
  • Figure 231: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%)
  • Figure 232: Novartis, Net Sales, 2013-2017 (USD Million)
  • Figure 233: Novartis, Revenue, By Segment, 2017(%)
  • Figure 234: Novartis, Revenue, By Region, 2017(%)
  • Figure 235: Cipla, Net Sales, 2013-2017 (USD Million)
  • Figure 236: Cipla , By Region, 2017(%)
  • Figure 237: Mylan, Net Sales, 2013-2017 (USD Million)
  • Figure 238: Mylan, By Region, 2017(%)
  • Figure 239: Vectura Group , Net Sales, 2013-2017 (USD Million)
  • Figure 240: Vectura Group, By Products, 2017(%)

List of Tables

  • Table A: Stages of COPD
  • Table B: Beta-2 Agonist Drugs For in COPD Treatment
  • Table C: Anti-muscarinic Drugs For COPD Treatment
  • Table D: Combination Bronchodilators Therapy For COPD Treatment
  • Table E: ICS Combination Therapy For COPD Treatment
  • Table F: EU-5 Socio-Economical Statistics, 2017
  • Table G: PT010 Clinical Trails
  • Table H: Other PT010 Phase-3 Trails
  • Table I: Primary endpoint results assessed by FEV1
  • Table J: Duaklir Clinical Trails
  • Table K: Statistical Analysis
  • Table L: Statistical Analysis
  • Table M: Statistical Analysis
  • Table N: Statistical Analysis
  • Table O: Statistical Analysis
  • Table P: Statistical Analysis
  • Table Q: Statistical Analysis
  • Table R: Statistical Analysis
  • Table S: Statistical Analysis
  • Table T: Danirixin Clinical Studies
  • Table U: Nemiralisib Clinical Studies
  • Table V: GSK2269557 Clinical Studies
  • Table W: Other Major Drugs In Development Pipeline
  • Table X: Product Benchmarking, By Drug Type
  • Table Y: GSK COPD Drugs Sales, 2017, USD Million
  • Table Z: AstraZeneca COPD Drugs Sales, 2017, USD Million
  • Table AB: Novartis COPD Drugs Sales, 2017, USD Million
  • Table AC: Boehringer Ingelheim COPD Drugs Sales, 2017, USD Million
  • Table AD: Product Benchmarking, By Drug Type
目次

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of COPD Drugs Market. The report analyses the COPD Drugs Market By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, and Others). The report analyses the COPD Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes pipeline analysis for few COPD drugs.

According to Azoth Analytics research report "Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition): Forecast to 2023 - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India)", the COPD drugs market is projected to display robust growth represented by a CAGR of 2.47% during 2018 - 2023.

Over the recent years, COPD Drugs market has been witnessing growth on account of several driving factors including growing prevalence of COPD associated diseases, rising patient population, and increase in availability of novel combination therapy drugs. Moreover, increasing awareness regarding COPD, high smoking prevalence, rising pollution level, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, and growing scope in middle and low income countries with large patient population is anticipated to impel the market growth of the COPD drugs market. However, growing portfolio of generic COPD drugs, and patent expiration of few innovator drugs in upcoming years are expected to hinder the market performance during forecasted period.

In this research report, the market is segmented on the basis of drug type. By drug type, the combination therapy COPD drugs are predicted to hold their dominant position in the market, especially LABA/LAMA and triple combination ICS/LABA/LAMA market is expected to gain more traction in forecasted period. Amongst the regions, North America accounts for the largest regional share in the global COPD drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and more emphasis towards prescribed branded drugs.

The report titled "Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition): Forecast to 2023 - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India" has covered and analysed the potential of COPD drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the COPD drugs market. Additionally, the report also highlights market entry strategies for various companies across the globe along with pipeline and product analysis.

Scope of the Report

Global COPD Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • COPD Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, and Other COPD Drugs.

Regional COPD Drugs Market - North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • COPD Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, and Other COPD Drugs.

Country Analysis - U.S., Canada, Germany, U.K, France, Italy, China, Japan, India (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • COPD Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, Other COPD Drugs.

Other Report Highlights

  • Pipeline Analysis- PT010, Duaklir, Nemiralisib, Danirixin.
  • Product Analysis.
  • Market Dynamics - Drivers and Restraints.
  • Market Trends.
  • Porter Five Forces Analysis.
  • SWOT Analysis.
  • Company Analysis - Glaxo SmithKline, AstraZeneca, Boehringer-Ingelheim, TEVA Pharmaceuticals, Chiesi Pharmaceuticals, Novartis, Merck, Cipla, Mylan, Vectura, Sunovion

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendation

  • 3.1 Invest in COPD Generic Drugs
  • 3.2 Asia Pacific Region To Witness The Fastest Growth

4. COPD Drugs Products Outlook

5. Global COPD Drugs Market: Growth and Forecast

  • 5.1 By Value (2013-2017)
  • 5.2 By Value (2018-2023)

6. Global COPD Drugs Market: Segmental Analysis

  • 6.1 Global COPD Drugs Market Size, By Drug Type: Breakdown (%)
    • 6.1.1 Global COPD Drugs Market Size, By Drug Type, 2017 (%)
    • 6.1.2 Global COPD Drugs Market Size, By Drug Type, 2023 (%)
  • 6.2 Global Combination Therapy COPD Drugs Market Size, By Value (2013-2023)
  • 6.3 Global Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
  • 6.4 Global Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
  • 6.5 Global ICS COPD Drugs Market Size, By Value (2013-2023)
  • 6.6 Global Other COPD Drugs Market Size, By Value (2013-2023)
  • 6.6 Global COPD Drugs: Market Attractiveness, By Drug Type

7. Global COPD Drugs Market: Regional Analysis

  • 7.1 Global COPD Drugs Market Size, By Region : Breakdown (%)
    • 7.1.1 Global COPD Drugs Market Size, By Region, 2017 (%)
    • 7.1.2 Global COPD Drugs Market Size, By Region, 2023 (%)

8. North America COPD Drugs Market: Growth and Forecast

  • 8.1 North America COPD Drugs Market: Segmental Analysis
  • 8.2 North America COPD Drugs Market Size, By Drug Type: Breakdown (%)
    • 8.2.1 North America COPD Drugs Market Size, By Drug Type, 2017 (%)
    • 8.2.2 North America COPD Drugs Market Size, By Drug Type, 2023 (%)
  • 8.3 North America Combination Therapy COPD Drugs Market Size, By Value (2013-2023)
  • 8.4 North America Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
  • 8.5 North America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
  • 8.6 North America ICS COPD Drugs Market Size, By Value (2013-2023)
  • 8.7 North America Other COPD Drugs Market Size, By Value (2013-2023)
  • 8.9 North America COPD Drugs Market: Country Analysis (U.S and Canada)
    • 8.9.1 U.S COPD Drugs Market, By Value (2013-2023)
    • 8.9.2 U.S COPD Drugs Market, By Drug Type, By Value (2013-2023)
    • 8.9.3 Canada COPD Drugs Market, By Value (2013-2023)
    • 8.9.4 Canada COPD Drugs Market, By Drug Type, By Value (2013-2023)

9. Europe COPD Drugs Market: Growth and Forecast

  • 9.1 Europe COPD Drugs Market: Segmental Analysis
  • 9.2 Europe COPD Drugs Market Size, By Drug Type: Breakdown (%)
    • 9.1.2 Europe COPD Drugs Market Size, By Drug Type, 2017 (%)
    • 9.1.3 Europe COPD Drugs Market Size, By Drug Type, 2023 (%)
  • 9.3 Europe Combination Therapy COPD Drugs Market Size, By Value (2013-2023)
  • 9.4 Europe America Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
  • 9.5 Europe America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
  • 9.6 Europe America ICS COPD Drugs Market Size, By Value (2013-2023)
  • 9.7 Europe America Other COPD Drugs Market Size, By Value (2013-2023)
  • 9.8 Europe COPD Drugs Market: Country Analysis (Germany, France, U.K, Italy)
    • 9.8.1 Germany COPD Drugs Market, By Value (2013-2023)
    • 9.8.2 Germany COPD Drugs Market, By Drug Type, By Value (2013-2023)
    • 9.8.4 France COPD Drugs Market, By Value (2013-2023)
    • 9.8.5 France COPD Drugs Market, By Drug Type, By Value (2013-2023)
    • 9.8.7 UK COPD Drugs Market, By Value (2013-2023)
    • 9.8.6 UK COPD Drugs Market, By Drug Type, By Value (2013-2023)
    • 9.8.7 Italy COPD Drugs Market, By Value (2013-2023)
    • 9.8.8 Italy COPD Drugs Market, By Drug Type, By Value (2013-2023)

10. APAC COPD Drugs Market: Growth and Forecast

  • 10.1 APAC COPD Drugs Market: Segmental Analysis
  • 10.2 APAC COPD Drugs Market Size, By Drug Type: Breakdown (%)
    • 10.2.1 APAC COPD Drugs Market Size, By Drug Type, 2017 (%)
    • 10.2.2 APAC COPD Drugs Market Size, By Drug Type, 2023 (%)
  • 10.3 APAC Combination Therapy COPD Drugs Market Size, By Value (2013-2023)
  • 10.4 APAC Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
  • 10.5 APAC Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
  • 10.6 APAC ICS COPD Drugs Market Size, By Value (2013-2023)
  • 10.7 APAC Other COPD Drugs Market Size, By Value (2013-2023)
  • 10.8 APAC COPD Drugs Market: Country Analysis (China, Japan, and India)
    • 10.8.1 China COPD Drugs Market, By Value (2013-2023)
    • 10.8.2 China COPD Drugs Market, By Drug Type, By Value (2013-2023)
    • 10.8.3 Japan COPD Drugs Market, By Value (2013-2023)
    • 10.8.4 Japan COPD Drugs Market, By Drug Type, By Value (2013-2023)
    • 10.8.5 India COPD Drugs Market, By Value (2013-2023)
    • 10.8.6 India COPD Drugs Market, By Drug Type, By Value (2013-2023)

11. ROW COPD Drugs Market: Growth and Forecast

  • 11.1 ROW COPD Drugs Market: Segmental Analysis
  • 11.2 ROW COPD Drugs Market Size, By Drug Type: Breakdown (%)
    • 11.1.1 ROW COPD Drugs Market Size, By Drug Type, 2017 (%)
    • 11.1.2 ROW COPD Drugs Market Size, By Drug Type, 2023 (%)
  • 11.3 ROW Combination Therapy COPD Drugs Market Size, By Value (2013-2023)
  • 11.4 ROW Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
  • 11.5 ROW Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
  • 11.6 ROW ICS COPD Drugs Market Size, By Value (2013-2023)
  • 11.7 ROW Other COPD Drugs Market Size, By Value (2013-2023)

12. Global COPD Drugs Market: Pipeline Analysis

13. Global COPD Drugs Market: Market Dynamics

  • 13.1 Global COPD Drugs Market: Drivers
  • 13.2 Global COPD Drugs Market: Restrains
  • 13.3 Global COPD Drugs Market: Trends
  • 13.4 Global COPD Drugs Market: Product Benchmarking
  • 13.5 Global COPD Drugs Market: Sales Analysis, By Company

14. Porter Five Force Analysis

15. SWOT Analysis

16. Company Profiles

  • 16.1 GSK
  • 16.2 AstraZeneca
  • 16.3 Boehringer-Ingelheim
  • 16.4 Teva Pharmaceuticals
  • 16.5 Chiesi Farmaceutici S.p.A.
  • 16.6 Novartis
  • 16.7 Cipla
  • 16.8 Mylan
  • 16.9 Vectura Group Plc,
  • 16.10 Sunovion
Back to Top